P.137 Reachable workspace to evaluate efficacy of losmapimod in subjects with FSHD in two phase 2 studies
Assess efficacy of losmapimod to slow or stop disease progression with reachable workspace (RWS). RWS is a 3D assessment of function that measures upper extremity mobility. Fulcrum is developing losmapimod (LOS; a small molecule inhibitor of p38 α/β MAPK) to treat FSHD. Eighty subjects (N=40/group)...
Saved in:
| Published in | Neuromuscular disorders : NMD Vol. 32; p. S104 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier B.V
01.10.2022
|
| Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!